uniQure N.V. QURE

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.

• GlobeNewswire Inc. 30 sept

  UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights

  Law firm Kirby McInerney LLP is investigating potential securities law violations by uniQure N.V. following the release of 48-month data for AMT-130 that showed significantly reduced treatment efficacy (44% disease slowing) compared to previously reported 36-month results (75% slowing). The company had submitted an FDA application based on the stronger 36-month data. uniQure's stock price declined 37.3% on the news, falling from $39.11 to $24.51 per share.

  

• Zacks Investment Research 30 sept

  uniQure Plunges on Additional Data From Huntington's Disease Study

  uniQure (QURE) announced mixed phase I/II data for its investigational gene therapy ifezuntirgene inilparvovec for Huntington's disease treatment. At 36 months, the therapy showed 80% slowing in cUHDRS and 67% in TFC versus external controls. However, 48-month data showed weaker results with cUHDRS at 44% slowing (not statistically significant) and TFC at 61% slowing. The stock plunged 37% following the announcement. The company has submitted a BLA to the FDA based on 36-month data, with regulatory review and durability validation as key upcoming catalysts.

  

• GlobeNewswire Inc. 29 sept

  QURE Investor Alert: uniQure Securities Investigation - Kehoe Law Firm, P.C.

  uniQure N.V. experienced a significant stock decline of over 35% on September 29, 2026, following the release of updated 48-month data for AMT-130, its investigational gene therapy for Huntington's disease. The disappointing results have prompted a securities investigation by Kehoe Law Firm on behalf of affected investors.

  

• Zacks Investment Research 3 sept

  Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?

  Spyre Therapeutics shares have declined 16.6% since its Q2 2026 earnings report, underperforming the S&P 500. The company reported a narrower-than-expected loss of 36 cents per share and benefited from a $40 million gain on asset sales, though R&D expenses surged 63.2% year-over-year. With $1.15 billion in cash expected to fund operations into late 2029, analyst estimates have shifted downward by 10.44%, and the stock holds a Zacks Rank #3 (Hold) rating.

  

• GlobeNewswire Inc. 23 jun

  uniQure Announces Pricing of Upsized $225 Million Public Offering

  uniQure N.V. announced the pricing of an underwritten public offering of 4,945,055 ordinary shares at $45.50 per share, generating approximately $225 million in gross proceeds. The offering is expected to close on June 25, 2026. The company is advancing gene therapies for hemophilia B, Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, and other severe conditions.